+ All Categories
Home > Documents > ESG WAY SERIES EDELWEISS ESG WAY SERIES

ESG WAY SERIES EDELWEISS ESG WAY SERIES

Date post: 25-Nov-2021
Category:
Upload: others
View: 4 times
Download: 0 times
Share this document with a friend
13
We argue that the Social quotient within ESG will gain greater prominence as a fall out of the COVID-19 outbreak. Even prior to the outbreak, Corporate India’s social disclosure had nearly doubled, and now in fact, is higher than that of US and EU. We believe Indian companies have a significant opportunity to enhance goodwill with consumers and the government. In most cases, this can be done at no significant increase in cost as COVID-19 spends qualify for inclusion within CSR. Some sectors may even benefit, including telecom (data consumption), pharma, consumer staples and retail. On the other hand, the burden may disproportionately fall on banks (enhanced NPAs), hospitals (cost-base services) and health insurance companies. But, in all cases, eventual economic benefit of goodwill gained will outweigh near-term costs. India’s Social quotient pips US and EU; IT and cement take lead Our analysis indicates that Indian corporatesSocial disclosure scores have nearly doubled over the past six years and, in fact, are even higher than that of US and EU. However, in India, the investor community's ESG thought process has largely focused on Governance (G) and to a lesser extent on Environment (E) and Social (S). COVID-19 has the potential to change this permanently and get the Social quotient on an equal footing with G. We demonstrate that while India’s technology, cement and engineering sectors surpass global peers, BFSI, FMCG/retail and pharma lag. Furthermore, GAIL, TCS, Infosys, SAIL and ACC lead the Social quotient among India’s top 100 companies. Corporates leveraging existing expertise to ramp-up COVID-19 fight Beyond monetary contributions, Indian companies are leveraging their business expertise to provide more specific services in their respective fields. Some of the first companies off the block include Reliance Industries (RIL) leveraging its significant logistical, retail and data capabilities; Hindustan Unilever (HUL) making some hygiene products more affordable; Mahindra Group’s plan to manufacture ventilators; Axis Bank and Vedanta Group have committed contributions of INR1bn each. Goodwill gains sans significant increase in cost While corporate initiatives may not directly enhance business, it provides an opportunity for corporatesto showcase their ESG quotient and create goodwill with the government as well as customers. The government has announced that spends towards COVID-19 will qualify under CSR. Hence, we believe costs may not increase significantly as a result, but may mostly substitute other existing CSR spends. Banks, hospitals, insurance to bear brunt; staples, telecom to gain Potential bankruptcies may increase bank NPAs; similarly, health insurance claims could rise and hospitals may have to treat COVID-19 patients at cost. On the other hand, some sectors may even benefit---telecom (rise in data consumption), pharma (panic buying), consumer staples and retail (primarily groceries). COVID-19: Testing Corporate India’s Social quotient Edelweiss Research is also available on www.edelresearch.com, Bloomberg EDEL <GO>, Thomson First Call, Reuters and Factset. Edelweiss Securities Limited EDELWEISS ‘ESG WAY’ SERIES ESG WAY SERIES ESG report repository India 2025 - Seeking Growth The ESG Way Global ESG juggernaut accelerates; calling on India UK-India ESG Forum Mind the gap ESG Disclosures levels: Lagging but catching up Tobacco versus Alcohol: Is ESG reshaping valuations? CARO 2020: Tightening the governance grip March 26, 2020 Jal Irani +91 22 6620 3087 [email protected] Alok Deshpande +91 22 6620 3163 [email protected] Aditya Narain +91-22-6620 3061 [email protected] Vinayak Agarwal +91-22-6620 3020 [email protected]
Transcript
Page 1: ESG WAY SERIES EDELWEISS ESG WAY SERIES

1 Edelweiss Securities Limited

We argue that the Social quotient within ESG will gain greater prominence as a fall out of the COVID-19 outbreak. Even prior to the outbreak, Corporate India’s social disclosure had nearly doubled, and now in fact, is higher than that of US and EU. We believe Indian companies have a significant opportunity to enhance goodwill with consumers and the government. In most cases, this can be done at no significant increase in cost as COVID-19 spends qualify for inclusion within CSR. Some sectors may even benefit, including telecom (data consumption), pharma, consumer staples and retail. On the other hand, the burden may disproportionately fall on banks (enhanced NPAs), hospitals (cost-base services) and health insurance companies. But, in all cases, eventual economic benefit of goodwill gained will outweigh near-term costs.

India’s Social quotient pips US and EU; IT and cement take lead

Our analysis indicates that Indian corporates’ Social disclosure scores have nearly

doubled over the past six years and, in fact, are even higher than that of US and EU.

However, in India, the investor community's ESG thought process has largely focused

on Governance (G) and to a lesser extent on Environment (E) and Social (S). COVID-19

has the potential to change this permanently and get the Social quotient on an equal

footing with G. We demonstrate that while India’s technology, cement and engineering

sectors surpass global peers, BFSI, FMCG/retail and pharma lag. Furthermore, GAIL,

TCS, Infosys, SAIL and ACC lead the Social quotient among India’s top 100 companies.

Corporates leveraging existing expertise to ramp-up COVID-19 fight

Beyond monetary contributions, Indian companies are leveraging their business

expertise to provide more specific services in their respective fields. Some of the first

companies off the block include Reliance Industries (RIL) leveraging its significant

logistical, retail and data capabilities; Hindustan Unilever (HUL) making some hygiene

products more affordable; Mahindra Group’s plan to manufacture ventilators; Axis

Bank and Vedanta Group have committed contributions of INR1bn each.

Goodwill gains sans significant increase in cost While corporate initiatives may not directly enhance business, it provides an

opportunity for corporates’ to showcase their ESG quotient and create goodwill with

the government as well as customers. The government has announced that spends

towards COVID-19 will qualify under CSR. Hence, we believe costs may not increase

significantly as a result, but may mostly substitute other existing CSR spends.

Banks, hospitals, insurance to bear brunt; staples, telecom to gain Potential bankruptcies may increase bank NPAs; similarly, health insurance claims could

rise and hospitals may have to treat COVID-19 patients at cost. On the other hand,

some sectors may even benefit---telecom (rise in data consumption), pharma (panic

buying), consumer staples and retail (primarily groceries).

COVID-19: Testing Corporate India’s Social quotient

Vinayak - Paste past ESG reports

links here (including Kotak

Committee report & the recent one

Nilesh published)

November28, 2019 Edelweiss Research is also available on www.edelresearch.com, Bloomberg EDEL <GO>, Thomson First Call, Reuters and Factset. Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

ESG WAY SERIES

Jal Irani

+91 (22)6620 3163

[email protected]

Alok Deshpande

+91 (22) 6620 3163

[email protected]

Aditya Naraian

+91 (22) 6620 3163

Vinayak Agarwal

+91 (22) 6620 3163

ESG report repository India 2025 - Seeking Growth The ESG Way Global ESG juggernaut accelerates; calling on India UK-India ESG Forum – Mind the gap ESG Disclosures levels: Lagging but catching up Tobacco versus Alcohol: Is ESG reshaping valuations? CARO 2020: Tightening the governance grip

March 26, 2020

Jal Irani

+91 22 6620 3087

[email protected]

Alok Deshpande

+91 22 6620 3163

[email protected]

Aditya Narain

+91-22-6620 3061

[email protected]

Vinayak Agarwal

+91-22-6620 3020

[email protected]

Page 2: ESG WAY SERIES EDELWEISS ESG WAY SERIES

2 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

India’s Social quotient pips US and EU

Chart 1: Social disclosure scores of Indian corporates have risen sharply….

Source: Bloomberg, Edelweiss research

Chart 2: …and India’s Social scores are, in fact, highest globally

Source: Bloomberg, Edelweiss research

22.0

26.8

31.6

36.4

41.2

46.0

18.0

27.4

36.8

46.2

55.6

65.0

FY12 FY14 FY16 FY18

Dis

clo

sure

sco

re

E S G ESG (RHS)

20

32

44

56

68

80

Overall ESG Environment Social Governance

(Sco

re)

India Europe US Global

Page 3: ESG WAY SERIES EDELWEISS ESG WAY SERIES

3 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

IT and cement companies lead India’s Social quotient

Chart 3: IT and cement lead; BFSI and pharma lag India’s Social disclosures

Source: Bloomberg, Edelweiss research

GAIL, TCS, Infosys, SAIL, ACC lead India’s Social quotient

Chart 4: Social disclosure scores of top 20 (Nifty 100) companies

Source: Bloomberg

0

12

24

36

48

60

IT

Ce

me

nt

Engg

.

Oil

and

Gas

Me

tals

Po

we

r

Tele

com

Au

to

FMC

G/R

eta

il

Ph

arm

a

BFS

I

(So

cial

Dis

c. S

core

)

India Global

39.0

51.0

63.0

75.0

87.0

99.0

GA

IL

TCS

Info

sys

SAIL

AC

C

Hav

ells

Bo

sch

NM

DC

M&

M

L&T

HP

CL

ITC

JSW

Ste

el

Co

al In

dia

Tech

M

AB

B

Yes

Ban

k

Am

bu

ja

Re

lian

ce

NTP

C

(So

cial

dis

clo

sure

sco

re)

Page 4: ESG WAY SERIES EDELWEISS ESG WAY SERIES

4 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

CSR regulations in India

The corporate social responsibility (CSR) movement began as a response to advocacy for

corporations to play a role in ameliorating social problems due to their economic power

and overarching presence in daily life. The movement transitioned from its reliance on

purely voluntary activity to the greater use of laws. The push for legalisation came

because voluntary CSR presented problems such as free-riding (companies taking

advantage of benefits without actually spending), greenwashing posing as CSR and false

disclosures.

As per the amended Companies Act 2013, the Government of India has made it

mandatory for all companies meeting specific financial threshold to spend 2% of their

average net profit of the last three years on CSR activities. In other words, companies

“having net worth of INR5bn or more, or turnover of INR10bn or more or a net profit of

INR50mn or more during any financial year” have to ensure that they spend 2% of

average net profits made during the three preceding years on CSR activities.

Recently, the Ministry of Corporate Affairs (MCA) announced that funds spent on

measures to tackle the COVID-19 outbreak will be counted towards the CSR activity of

companies. The MCA said that funds spent on promotion of healthcare, including

preventive healthcare and sanitation and on disaster management, will be within the

definition of a company’s CSR obligations.

Fig. 1: Snapshot of MCA’s recent circular on spending of CSR funds for COVID-19

Source: Ministry of Corporate Affairs (MCA)

Page 5: ESG WAY SERIES EDELWEISS ESG WAY SERIES

5 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

CSR compliance improving with time

The total number of CSR projects in FY18-19 was 6,131. The prescribed CSR spend was

INR108.7bn, while the actual CSR spend was INR109.0bn. The higher CSR compliance

indicates a renewed sense of seriousness amongst companies as they have strived to

match or surpass the prescribed CSR requirements.

Of the 368 companies examined in the report, 63% spent more than the prescribed CSR,

10% spent as prescribed and 27% spent less than the prescribed CSR. In terms of

individual companies, RIL, NTPC, ONGC and Power Grid Corporation spent more than

their prescribed CSR budgets in FY19.

Chart 5: Actual CSR expenditure versus prescribed

Source: India CSR Outlook Report 2019

70.0

78.0

86.0

94.0

102.0

110.0

FY15 FY16 FY17 FY18 FY19

3,500

28,500

53,500

78,500

1,03,500

1,28,500

(%)

(IN

Rm

n)

Prescribed CSR spend Actual CSR spend

Actual CSR spend as % of Prescribed

Page 6: ESG WAY SERIES EDELWEISS ESG WAY SERIES

6 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

Corporate India proudly steps-up in COVID-19 fight

We believe Indian corporates have been quick to announce significant initiatives towards

their fight against COVID-19, which will sharply enhance their Social quotient under the

ESG umbrella. Wisely, most are leveraging their existing significant business capabilities to

deliver quick and effective results. We highlight some of the most significant initiatives by

those corporates who are amongst the first off the block.

Reliance Industries steps up fight against COVID-19

We believe the RIL Group is amongst the first to announce comprehensive plans towards

its fight against COVID-19, which will sharply enhance its Social quotient.

Key additional recent steps undertaken: A dedicated 100-bed COVID-19 hospital facility;

free fuel for emergency vehicles; production of 0.1m face masks pd & PPEs for health

workers, in addition to those discussed below.

Leveraging various business capabilities: While RIL’s initiatives may not directly enhance

business, they will create huge goodwill with the government as well as customers. Key

initiatives include the significant logistical capability and sheer determination to keep its

736 grocery stores open to cater to more than 400mn customers (one-third of India’s

population); leveraging IOT capabilities such as JioHaptikChatbot powering MyGov

Corona Helpdesk as part of Health-care at Home; free 10Mbps JioFiber broadband

connectivity; double 4G data add-on vouchers.

At no significant additional cost: RIL spent ~INR9bn under CSR last year. The government

has allowed corporates to include costs towards the COVID-19 fight under CSR.

Corporates are required to spend a minimum 2% of past three years’ net profit towards

CSR. Hence, we believe RIL’s costs may not increase significantly as a result of this cause.

For greater details of RIL’s initiatives, please refer to the company’s website link.

https://www.ril.com/getattachment/bacdc6ec-6dc1-4f28-a10c-d63bb467a7d6/Reliance-

Industries-further-Steps-Up-its-Support-t.aspx

Cipla sees opportunity in tackling COVID-19 as it did in HIV

Cipla has consistently worked for people’s access to much-needed medical drugs across

the world. Its corporate ethos is caring for life and goes way beyond just driving a safe

and profitable multi-market business. In 2000, Chairman Dr. Yusuf Hamied stunned the

pharma world by offering a dollar a day cocktail of three drugs to treat AIDS. The

company hopes to achieve similar outcome with a repurposed version of its HIV drug

lopinavir-ritonavir in the world’s fight against COVID-19. The company has also come

forward to engage with the CSIR-IICT to take up manufacture of three promising ARVs –

favipiravir, remdesivir and baloxavir – to treat COVID-19.

The company’s corporate responsibility vision is to achieve the distinction of being

acknowledged as an admirable and trusted company. It spends INR300mn plus each year

on CSR activities. CSR initiatives themed on Health, Education, Skilling & Disaster Relief

were mainly undertaken through Cipla Foundation, which works with institutions, NGOs,

government agencies, domain experts and other philanthropic foundations to enhance

the outreach of CSR initiatives.

Page 7: ESG WAY SERIES EDELWEISS ESG WAY SERIES

7 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

Link to Cipla Foundation

https://www.cipla.com/cipla-foundation

HUL commits INR1bn to fight against Coronavirus

HUL has always been a socially responsible company and its actions during this pandemic

further strengthens the claim.

Key initiatives undertaken/will be undertaken:

HUL will donate 20million pieces of Lifebuoy soaps in the next few months to sections

of society which need them the most.

It is cutting prices of Lifebuoy sanitizers, Lifebuoy liquid handwash and Domex floor

cleaners by 15% and is commencing production of these reduced-priced products

immediately. These will be available in the market in the next few weeks.

HUL will donate INR100mn to upgrade healthcare facilities in testing centres and

hospitals.

Mr. Sanjiv Mehta, Chairman and Managing Director, HUL, said, “in a crisis like this,

companies have a big role to play. We are working closely with governments and our

partners to ensure that we overcome this global health crisis together.”

For greater details of HUL’s initiatives, please refer to the company’s website link.

https://www.hul.co.in/news/press-releases/2020/hul-stands-with-the-nation.html

Diageo India pledges support to fight Coronavirus

Diageo India, the country’s largest beverage alcohol company, has announced that it will

support the government and hospitality sector during this pandemic through the

manufacture of hand sanitisers from its 15 manufacturing units across the country,

donation of ENA to the sanitiser industry, health insurance cover to on-trade partners and

donation of free masks to government public health departments.

Mr. AnandKripalu, Managing Director and CEO, United Spirits, said, “we stand united with

the government and citizens of our country in the fight against Coronavirus. The demand for

sanitisers is increasing by the hour and we would like to use our manufacturing units to join

in the effort to fill the demand-supply gap for sanitisers, so critical at this hour. Healthcare

providers are at the forefront of this fight and donating masks is a token of our appreciation

for their selfless dedication to fighting the epidemic. We also want to support our partners

in the hospitality industry, especially bartenders who are facing unprecedent challenges due

to closure of restaurants and bars”.

For more details - https://www.diageoindia.com/news-media/press-releases/diageo-india-

pledges-support-to-fight-coronavirus/

Page 8: ESG WAY SERIES EDELWEISS ESG WAY SERIES

8 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

Mahindra Group

Mr. Anand Mahindra has offered company resorts to be utilised as temporary care

facilities. Further, Mahindra’s projects team will be made available to assist the

government or army to erect temporary care facilities.

The Mahindra Group will immediately begin figuring out how its manufacturing

facilities can make ventilators.

He further announced that the Mahindra Foundation will create a fund to assist the

hardest-hit sections like small businesses and self-employed people in the economy

and the value chain. Mr. Mahindra has offered 100% of his salary to the fund.

Vedanta

Vedanta has set up a dedicated INR1bn fund as part of its endeavour to combat the

widespread outbreak of deadly COVID-19.

Tata Sons

Mr. N Chandrasekaran, Chairman, Tata Sons, has said that Tata Group will ensure full

payment to daily wage earners and contract workers.

https://www.thehindubusinessline.com/companies/how-india-inc-has-responded-to-

covid19-crisis/article31149238.ece#

SBI sets up emergency credit line for affected borrowers

According to SBI, businesses facing financial distress owing to the COVID-19 outbreak and

the measures taken to curb its spread will be able to apply for loans through the Emergency

Credit Line.

"The additional liquidity facility COVID-19 Emergency Credit Line (CECL), will provide funds

up to INR2bn and will be available till June 30, 2020," SBI said in a circular. Loans will be

offered at an interest rate of 7.25% and will have a tenure of 12 months.

Axis Bank

Axis Bank said it will set aside INR1bn to support its customers, employees, vendors and

government agencies towards curbing the spread of COVID-19.

Galaxy Surfactants

In order to equip the society and fight the threatening COVID-19 pandemic, employees of

Galaxy Surfactants set out to distribute over 700 kits of Dettol soaps and hand wash in

Talodaravillage, Gujarat.

Page 9: ESG WAY SERIES EDELWEISS ESG WAY SERIES

9 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

Appendix 1: Social disclosure score of companies in Nifty 100

Source: Bloomberg

Company Social disclosure score

GAIL 82.5

TCS 71.9

Infosys 70.2

SAIL 66.7

ACC 63.2

Havel ls 57.9

Bosch 57.9

NMDC 57.9

M&M 54.4

L&T 54.4

HPCL 54.4

ITC 54.4

JSW Steel 54.4

Coa l India 54.4

TechM 52.6

ABB 52.6

Yes Bank 51.7

Ambuja 49.1

Rel iance 49.1

NTPC 49.1

Oi l & Natura l Gas Corp Ltd 48.4

Vodafone Idea Ltd 48.4

Shree Cement Ltd 47.4

Ti tan Co Ltd 47.4

Cadi la Healthcare Ltd 47.4

Bharat Petroleum Corp Ltd 45.3

Wipro Ltd 43.9

Ul traTech Cement Ltd 43.9

Ashok Leyland Ltd 43.9

Bharat Heavy Electrica ls Ltd 43.9

Vedanta Ltd 43.9

HCL Technologies Ltd 43.9

Indian Oi l Corp Ltd 43.9

Hindustan Zinc Ltd 43.9

Power Grid Corp of India Ltd 43.9

Marico Ltd 42.1

Siemens Ltd 42.1

Indus Ind Bank Ltd 41.7

ICICI Lombard Genera l Insurance Co Ltd 41.7

Bharti Ai rtel Ltd 40.6

Axis Bank Ltd 40.0

Shri ram Transport Finance Co Ltd 40.0

Maruti Suzuki India Ltd 38.6

Godrej Consumer Products Ltd 38.6

UPL Ltd 38.6

Petronet LNG Ltd 38.6

DLF Ltd 38.6

Biocon Ltd 38.6

Colgate-Pa lmol ive India Ltd 38.6

Company Social disclosure score

Baja j Auto Ltd 38.6

InterGlobe Aviation Ltd 38.6

Conta iner Corp Of India Ltd 38.6

United Breweries Ltd 38.6

Bharti Infratel Ltd 36.8

Indiabul ls Hous ing Finance Ltd 36.7

Adani Ports & Specia l Economic Zone Ltd 33.3

Hindustan Uni lever Ltd 33.3

As ian Pa ints Ltd 33.3

Tata Motors Ltd 33.3

Dabur India Ltd 33.3

Pi ramal Enterprises Ltd 33.3

Ba ja j Finance Ltd 33.3

Page Industries Ltd 33.3

Zee Enterta inment Enterprises Ltd 33.3

Aurobindo Pharma Ltd 33.3

NHPC Ltd 33.3

Gujarat State Petronet 33.3

Apol lo Hospita ls 33.3

State Bank of India 31.7

HDFC Li fe Insurance Co Ltd 31.7

Cipla Ltd/India 31.6

Kotak Mahindra Bank Ltd 30.0

Bri tannia Industries Ltd 28.1

Hero MotoCorp Ltd 28.1

Tata Steel Ltd 28.1

Hindalco Industries Ltd 28.1

Divi 's Laboratories Ltd 28.1

Lupin Ltd 28.1

Eicher Motors Ltd 28.1

MRF Ltd 28.1

ICICI Bank Ltd 26.7

Procter & Gamble Hygiene & Health Care L 24.6

Pidi l i te Industries Ltd 22.8

Avenue Supermarts Ltd 22.8

Gras im Industries Ltd 22.8

Sun Pharmaceutica l Industries Ltd 22.8

Motherson Sumi Systems Ltd 22.8

HDFC Bank Ltd 21.7

ICICI Prudentia l Li fe Insurance Co Ltd 21.7

Indraprastha Gas 17.5

SBI Li fe Insurance Co Ltd 16.7

Bank of Baroda 16.7

Oracle Financia l Services Software Ltd 12.3

Hous ing Development Finance Corp Ltd 11.7

L&T Finance Holdings Ltd 8.3

Bharat Forget Ltd 8.3

United Spiri ts Ltd 7.0

Ba ja j Finserv Ltd 5.0

Page 10: ESG WAY SERIES EDELWEISS ESG WAY SERIES

10 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

Edelweiss Securities Limited, Edelweiss House, off C.S.T. Road, Kalina, Mumbai – 400 098.

Board: (91-22) 4009 4400, Email: [email protected]

Aditya Narain

Head of Research

[email protected]

Page 11: ESG WAY SERIES EDELWEISS ESG WAY SERIES

11 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

DISCLAIMER

Edelweiss Securities Limited (“ESL” or “Research Entity”) is regulated by the Securities and Exchange Board of India (“SEBI”) and is licensed to carry on the business of broking, depository services and related activities. The business of ESL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

This Report has been prepared by Edelweiss Securities Limited in the capacity of a Research Analyst having SEBI Registration No.INH200000121 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ESL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. ESL reserves the right to make modifications and alterations to this statement as may be required from time to time. ESL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. ESL is committed to providing independent and transparent recommendation to its clients. Neither ESL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of ESL. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of ESL and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

ESL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the ESL to present the data. In no event shall ESL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the ESL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

ESL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. ESL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with ESL.

Page 12: ESG WAY SERIES EDELWEISS ESG WAY SERIES

12 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

ESL or its associates may have received compensation from the subject company in the past 12 months. ESL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. ESL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. ESL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. ESL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or ESL’s associates may have financial interest in the subject company. ESL and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. ESL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: ( i) exchange rates can be volatile and are subject to large fluctuations; ( ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

ESL has financial interest in the subject companies: No

ESL’s Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

ESL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by ESL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years except that ESL had submitted an offer of settlement with Securities and Exchange commission, USA (SEC) and the same has been accepted by SEC without admitting or denying the findings in relation to their charges of non registration as a broker dealer.

A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimers

Disclaimer for U.S. Persons

This research report is a product of Edelweiss Securities Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Edelweiss Securities Limited only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

Page 13: ESG WAY SERIES EDELWEISS ESG WAY SERIES

13 Edelweiss Securities Limited

EDELWEISS ‘ESG WAY’ SERIES

Access the entire repository of Edelweiss Research on www.edelresearch.com

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Edelweiss Securities Limited has entered into an agreement with a U.S. registered broker-dealer, Edelweiss Financial Services Inc. ("EFSI"). Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc. Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the “Order”); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”). This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. Disclaimer for Canadian Persons

This research report is a product of Edelweiss Securities Limited ("ESL"), which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst. This report is intended for distribution by ESL only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person. ESL is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) ESL is not registered in the Province of Ontario to trade in securities nor is it registered in the Province of Ontario to provide advice with respect to securities; (ii) ESL's head office or principal place of business is located in India; (iii) all or substantially all of ESL's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against ESL because of the above; and (v) the name and address of the ESL's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario M5J 2T3 Canada. Disclaimer for Singapore Persons

In Singapore, this report is being distributed by Edelweiss Investment Advisors Private Limited ("EIAPL") (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to EIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact EIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

Copyright 2009 Edelweiss Research (Edelweiss Securities Ltd). All rights reserved


Recommended